"Slapp bremsen, vant nobel" morgenbladet.no/aktuelt/2018/1… via Morgenbladet

This month, we are expecting topline results from the randomized Phase II study NIPU in malignant pleural #mesothelioma. BioStock had a chat with our Director of Medical Affairs Espen Basmo Ellingsen about the disease: #pleuralmesothelioma #CancerResearch #immunotherapy #biotech

Ultimovacs i mål med rekruttering til studie på hode - og halskreft: Studien der Ultimovacs universelle kreftvaksine UV1 skal prøves ut i kombinasjon med sjekkpunkthemmeren Keytruda, er nå fullrekruttert. #biotech #medwatch #immunterapi MedWatch News medwatch.no/nyheter/legemi…

Our paper on UV1 in combination with pembrolizumab is out in Clinical Cancer Research. Encouraging results in advanced melanoma. Randomized trial of UV1 in combination with ipilimumab and nivolumab is ongoing, with expected readout second half of 2023. #CancerVaccine Yousef Zakharia

Looking forward to presenting data on our therapeutic cancer vaccine, UV1, at #PIVAC23 next week!

Some great work coming out of Oslo! Catch up on the long-term follow-up of three phase I clinical trials of UV1 in this #JITC article from Espen Basmo Ellingsen et al as you head to the 15:15 CET presentation of LBA99 (NIPU trial) from Åslaug Helland at #ESMO23. bit.ly/46BZkHg

Read the interview with Espen Basmo Ellingsen in Drug Target Review - Immuno-oncology innovations redefining cancer treatment in 2024 #CancerResearch #immunotherapy #biotech drugtargetreview.com/article/125151…

Survival-data from the NIPU-trial randomising pts with pleural mesotheliom to double ICI alone or with telomerase vaccine UV1. sciencedirect.com/science/articl…